CMV and EBV specific peptide-stimulated T cell (HS Diagnomics)

N/A

Report date: 2022/12/31 17:22:14

Base Information

Drug NameCMV and EBV specific peptide-stimulated T cell (HS Diagnomics)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Virus-specific T Cell therapy

Mechanisms of ActionT lymphocyte replacements

TargetsNot applicable

Therapy Area/IndicationsHematopoietic stem cell transplantation (HSCT)

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesHs Diagnomics Helmholtz Zentrum Munchen Universitatsmedizin Berlin

China Registration ClassN/A

Develop Information

Active CompaniesUniversitatsmedizin Berlin Helmholtz Zentrum Munchen Hs Diagnomics

Inactive CompaniesN/A

Active IndicationsHematopoietic stem cell transplantation (HSCT)

Inactive IndicationsN/A

Other Information

ATC CodeN/A